AWM
GRCE

AE Wealth Management’s Grace Therapeutics GRCE Stock Holding History

AE Wealth Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-274
Closed -$4K – 1585
2020
Q4 		$4K Buy
+274
New +$3.17K ﹤0.01% 1351

Other funds holding GRCE

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return

AE Wealth Management's GRCE Position: Q1 2021 in Review

AE Wealth Management sold out of Grace Therapeutics (GRCE) in Q1 2021, closing a stake of 274 shares — an estimated $4K sold.

AE Wealth Management first reported a position in GRCE in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 24 funds tracked by Wall St. Rank hold GRCE as of Q1 2021.

  • AE Wealth Management reported no remaining Grace Therapeutics position as of Q1 2021 after selling out during the quarter.
  • AE Wealth Management sold 274 Grace Therapeutics shares in Q1 2021, an estimated $4K.
  • AE Wealth Management first reported a position in Grace Therapeutics in Q4 2020 and held it in 1 quarter.
  • AE Wealth Management's Grace Therapeutics position peaked at $4K in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2021.

Based on AE Wealth Management's 13F filing for Q1 2021, filed 27 Apr 2021.